Cargando…

CheckMate 214 trial: Immune checkpoint regulators for advanced renal cell carcinoma

Detalles Bibliográficos
Autor principal:	Jena, Rahul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2020
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7531367/ https://www.ncbi.nlm.nih.gov/pubmed/33082645 http://dx.doi.org/10.4103/iju.IJU_153_20

Ejemplares similares

Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
por: Tarigopula, Vivek
Publicado: (2022)

Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
por: Kumar, Naveen
Publicado: (2021)

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
por: Regan, Meredith M., et al.
Publicado: (2021)

CheckMATE tutorial
por: Kim, Jong Soo, et al.
Publicado: (2021)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Temsirolimus, interferon alfa or both in advanced renal-cell carcinoma: One plus one does not always equal two
por: Grover, S., et al.
Publicado: (2007)

Implementation of ML searches in CheckMATE
por: Rolbiecki, Krzysztof
Publicado: (2022)

Recent developments in CheckMATE 2
por: Wang, Zeren Simon
Publicado: (2021)

KEYNOTE-564: Adjuvant immunotherapy for renal cell carcinoma
por: Pandey, Abhishek
Publicado: (2022)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Implementation of multi-bin searches in CheckMATE
por: Lara Perez, Iñaki
Publicado: (2022)

Nectin-4 inhibitors: An ace up our sleeve against advanced urothelial carcinoma
por: Kumaraswamy, Santosh
Publicado: (2021)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

Prognostic stratification of renal cell carcinoma using a pathological triad of microvascular invasion, Fuhrman's grade and tumor size
por: Prakash, Gagan, et al.
Publicado: (2007)

PROFOUND trial –a new era in targeted therapeutics for prostate carcinoma
por: Tosh, Jyoti Mohan
Publicado: (2022)

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
por: Deng, Haiyi, et al.
Publicado: (2021)

POUT trial: Perioperative chemotherapy in upper tract urothelial carcinoma – A standard of care?
por: Ranjan, Satish Kumar
Publicado: (2020)

First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial
por: Kumaraswamy, Santosh
Publicado: (2021)

Comparison of multiparametric ultrasound versus multiparametric magnetic resonance imaging for diagnosis of carcinoma prostate: The CADMUS trial
por: Tarigopula, Vivek
Publicado: (2022)

Should small renal masses be managed expectantly?
por: Singla, Manish, et al.
Publicado: (2007)

Role of atezolizumab therapy combined with platinum-based chemotherapy in untreated metastatic urothelial carcinoma – The new landscapes (IMvigor130 trial)
por: Misra, Ankit
Publicado: (2021)

Dual immune checkpoint inhibition in metastatic renal cell carcinoma: Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Schmidinger, M., et al.
Publicado: (2021)

Transplantation of kidneys with small renal tumors: A novel idea?
por: Grover, Sameer, et al.
Publicado: (2009)

Renal and testicular involvement in COVID-19 patients – implication for the urologist
por: Pandey, Abhisek
Publicado: (2020)

Is incidence of prostate cancer higher in patients with end stage renal disease?
por: Khochikar, Makarand V.
Publicado: (2007)

Increasing use of nephron sparing surgery for T1a renal tumors
por: Kumar, Rajeev
Publicado: (2007)

Simplified PADUA REnal nephrometry system: A refitted PADUA score
por: Sharma, Gopal
Publicado: (2020)

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma—the CheckMate-9ER trial
por: Kfoury, M., et al.
Publicado: (2021)

Partial nephrectomy for small renal tumors may prevent chronic kidney disease
por: Kumar, Rajeev
Publicado: (2008)

Endocrine treatment in advanced prostate cancer: When to start?
por: Choudhrie, A. V., et al.
Publicado: (2009)

CheckMate 227 trial has not checked the immune-strategy in first-line setting in advanced non-small cell lung cancer
por: Remon, Jordi, et al.
Publicado: (2020)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
por: Emamekhoo, Hamid, et al.
Publicado: (2021)

Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
por: Regan, Meredith M, et al.
Publicado: (2021)

EWino searches in CheckMate and $(g-2)_\mu$ in the MSSM
por: Chakraborti, Manimala
Publicado: (2021)

The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning
por: Agrawal, Sumit
Publicado: (2020)

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
por: Filley, Anna C., et al.
Publicado: (2017)

What is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ao0n75kl196hp9qubvsfvur8eq